Skip to main content

Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group.

Publication ,  Journal Article
Garabedian, LF; Zhang, F; Costa, R; Argetsinger, S; Ross-Degnan, D; Wharam, JF
Published in: Ann Intern Med
April 2024

BACKGROUND: Twenty-five states have implemented insulin out-of-pocket (OOP) cost caps, but their effectiveness is uncertain. OBJECTIVE: To examine the effect of state insulin OOP caps on insulin use and OOP costs among commercially insured persons with diabetes. DESIGN: Pre-post study with control group. SETTING: Eight states implementing insulin OOP caps of $25 to $30, $50, or $100 in January 2021, and 17 control states. PARTICIPANTS: Commercially insured persons with diabetes and insulin users younger than 65 years. Subgroups of particular interest included members from states with insulin OOP caps of $25 to $30, enrollees with health savings accounts (HSAs) that require high insulin OOP payments, and lower-income members. MEASUREMENTS: Mean monthly 30-day insulin fills and OOP costs. RESULTS: State insulin caps were not associated with changes in insulin use in the overall population (relative change in fills per month, 1.8% [95% CI, -3.2% to 6.9%]). Insulin users in intervention states saw a 17.4% (CI, -23.9% to -10.9%) relative reduction in insulin OOP costs, largely driven by reductions among HSA enrollees; there was no difference in OOP costs among nonaccount plan members. More generous ($25 to $30) state insulin OOP caps were associated with insulin OOP cost reductions of 40.0% (CI, -62.5% to -17.6%), again primarily driven by a larger reduction in the subgroup with HSA plans. LIMITATIONS: Single national insurer; 9-month follow-up. CONCLUSION: Insulin OOP caps were associated with reduced insulin OOP costs but no overall increases in insulin use. A proposed national insulin cap of $35 for commercially insured persons might lead to meaningful insulin OOP savings but have a limited effect on insulin use. PRIMARY FUNDING SOURCE: Centers for Disease Control and Prevention and National Institute of Diabetes and Digestive and Kidney Diseases.

Duke Scholars

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

April 2024

Volume

177

Issue

4

Start / End Page

439 / 448

Location

United States

Related Subject Headings

  • United States
  • Insulin
  • Humans
  • Health Expenditures
  • General & Internal Medicine
  • Diabetes Mellitus
  • Cost Sharing
  • Control Groups
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Garabedian, L. F., Zhang, F., Costa, R., Argetsinger, S., Ross-Degnan, D., & Wharam, J. F. (2024). Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group. Ann Intern Med, 177(4), 439–448. https://doi.org/10.7326/M23-1965
Garabedian, Laura F., Fang Zhang, Rebecca Costa, Stephanie Argetsinger, Dennis Ross-Degnan, and J Frank Wharam. “Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group.Ann Intern Med 177, no. 4 (April 2024): 439–48. https://doi.org/10.7326/M23-1965.
Garabedian LF, Zhang F, Costa R, Argetsinger S, Ross-Degnan D, Wharam JF. Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group. Ann Intern Med. 2024 Apr;177(4):439–48.
Garabedian, Laura F., et al. “Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group.Ann Intern Med, vol. 177, no. 4, Apr. 2024, pp. 439–48. Pubmed, doi:10.7326/M23-1965.
Garabedian LF, Zhang F, Costa R, Argetsinger S, Ross-Degnan D, Wharam JF. Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group. Ann Intern Med. 2024 Apr;177(4):439–448.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

April 2024

Volume

177

Issue

4

Start / End Page

439 / 448

Location

United States

Related Subject Headings

  • United States
  • Insulin
  • Humans
  • Health Expenditures
  • General & Internal Medicine
  • Diabetes Mellitus
  • Cost Sharing
  • Control Groups
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences